Stereotactic body radiation therapy in patients with oligometastatic disease: Clinical state of the art and perspectives

R Kinj, E Muggeo, L Schiappacasse, J Bourhis… - Cancers, 2022 - mdpi.com
Simple Summary Stereotactic radiation therapy (SBRT) is a type of radiation therapy in
which a small number of high doses of radiation are delivered to a target volume using …

Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach

N Kim, H Kim, W Park, WK Cho, TG Kim, YH Im… - Radiation …, 2023 - Springer
Aim Patients with locoregionally uncontrolled breast tumors are frequently referred for breast
palliative radiotherapy (PRT) to mitigate symptoms. We analyzed the outcomes following …

Combination of olaparib with radiotherapy for triple‐negative breast cancers: one‐year toxicity report of the RADIOPARP phase I trial

P Loap, D Loirat, F Berger, K Cao… - … journal of cancer, 2021 - Wiley Online Library
Triple‐negative breast cancer (TNBC) cells are sensitive to PARP1 inhibitors in vitro. The
combination of Olaparib and radiotherapy for TNBC is currently evaluated in the Phase I …

Radiotherapy of the primary disease for synchronous metastatic cancer: a systematic review

Y Ghannam, A Laville, Y Kirova, I Latorzeff, A Levy… - Cancers, 2022 - mdpi.com
Simple Summary Local radiation treatment of the main tumors in patients with synchronous
metastatic illness has traditionally only been used for palliative purposes. The management …

Outcomes and toxicity of concurrent CDK4/6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer

A Beddok, V Mouren, P Cottu, F Laki… - … Journal of Cancer, 2023 - Wiley Online Library
The objective of the present study was to assess the outcomes and toxicity of patients
treated with concurrent administration of CDK4/6 inhibitors (CDK4/6i) and locoregional …

Pertuzumab and trastuzumab combination with concomitant locoregional radiotherapy for the treatment of breast cancers with HER2 receptor overexpression

A Aboudaram, P Loap, D Loirat, SB Dhia, K Cao… - Cancers, 2021 - mdpi.com
Simple Summary This retrospective study demonstrates that the combination of locoregional
breast RT with dual HER2 blockade by pertuzumab/trastuzumab was very well tolerated …

Aggressive local therapy for de novo metastatic breast cancer: Challenges and updates

B Liu, H Liu, M Liu - Oncology Reports, 2023 - spandidos-publications.com
Systemic therapy has been viewed as the mainstay for de novo metastatic breast cancer
(dnMBC). However, as dnMBC is highly heterogeneous both biologically and clinically, and …

Radiotherapy to the primary tumor: the first step of a tailored therapy in metastatic prostate cancer

M Ferro, F Crocetto, G Lucarelli, E Lievore, B Barone - Diagnostics, 2022 - mdpi.com
Prostate cancer is the first most frequent cancer in men worldwide, with over 250,000
estimated new cases diagnosed in 2021 [1]. Primary treatment modalities mostly include …

Is there a role for locoregional treatment of the primary tumor in de novo metastatic breast cancer in the era of tailored therapies?: Evidences, unresolved questions …

E Pons-Tostivint, E Alouani, Y Kirova, F Dalenc… - Critical reviews in …, 2021 - Elsevier
Improvements in systemic therapies have changed the face of de novo metastatic breast
cancer (dnMBC), with a 5-year survival rate exceeding 25%. Increasing evidence suggests …

Radiation therapy of the primary tumour and oligometastatic sites in patients with breast cancer with synchronous metastases: a literature review

R Le Scodan, Y Ghannam, Y Kirova, C Bourgier… - Cancer …, 2024 - Elsevier
De novo metastatic breast cancer represents 5 to 8% of all breast cancers (2500 new cases
per year in France). Systemic treatment is the cornerstone of treatment, whereas radiation …